|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.14 USD | -1.72% |
|
+0.10% | -6.40% |
| 02/05 | North American Morning Briefing : Stock Futures -3- | DJ |
| 30/04 | Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating | MT |
NeoGenomics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 156.24 million compared to USD 137.22 million a year ago. Net loss was USD 27.06 million compared to USD 30.8 million a year ago.
Basic loss per share from continuing operations was USD 0.21 compared to USD 0.25 a year ago. Diluted loss per share from continuing operations was USD 0.21 compared to USD 0.25 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -6.40% | 1.97B | |
| -16.80% | 8.79B | |
| +67.73% | 4.19B | |
| -4.03% | 2.48B | |
| -42.54% | 2.29B | |
| -20.34% | 1.56B | |
| -41.24% | 1.22B | |
| +10.26% | 1.13B | |
| +18.74% | 933M | |
| -10.93% | 910M |
NEOGENOMICS, INC. 